Alumis Inc. (“Alumis” or the “Company”), a clinical stage biopharmaceutical company developing oral therapies using a precision app...
Rapid Micro Biosystems, Inc. (the “Company” or “Rapid Micro”), an innovative life sciences technology company providing mission cri...
Medigene AG and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered a strategic co-development agreement to research and dev...
Strategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, and Expand Precision Medicine Applications in Cancer and Beyon...
Inventiva ("Inventiva" or the "Company"), a clinical-focused biopharmaceutical company focused on the development of orally administered small molecules fo...
LSPedia, a global leader in pharmaceutical traceability and supply chain SaaS solutions, has secured its second major U.S. government contract, the MMCAP I...
FDB (First Databank, Inc.), the leading provider of drug knowledge that helps healthcare professionals make precise medication decisions, will shine a spot...
Polycythemia Vera is a rare disorder marked by a continuous rise in the number of red blood cells in the blood, with an accompanying increase in white bloo...
Novita Pharmaceuticals, Inc. ("Novita"), a privately held, clinical-stage pharmaceutical company dedicated to developing novel cancer drugs through i...
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license application (sBLA) for...
Johnson & Johnson announced data from the Phase 3 ASTRO study of TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in adults with...
Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has determined the shortage of Wegovy® and Ozempic® is resolved. ...
The U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is ...
Ionis Pharmaceuticals, Inc. announced that it will present additional data from the pivotal Phase 3 OASIS and OASISplus studies, as well as three yea...
© 2025 Biopharma Boardroom. All Rights Reserved.
